Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Instagram Outage Disrupts Thousands of U.S. Users 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
ST. HELIER, Jersey, Sept. 30, 2016 -- In a press release issued under the same headline earlier today by Novocure, Ltd. (Nasdaq:NVCR), please note that the first paragraph should say "the three and nine months ended Sept. 30, 2016" rather than "the three and six months ended Sept. 30, 2016" as previously stated. The corrected release follows:
Novocure to Report Third Quarter 2016 Financial Results
Novocure (NASDAQ:NVCR) announced today that it will report financial results for the third quarter 2016 on Wednesday, Nov. 2, 2016, before the open of U.S.-based financial markets. Novocure management will host a conference call and webcast to discuss its financial results for the three and nine months ended Sept. 30, 2016, at 8 a.m. EDT on Wednesday, Nov. 2, 2016.
The conference call can be accessed by dialing 877-726-5929 for domestic callers and 530-379-4648 for international callers, using the conference ID 76871474. The webcast can be accessed live from the Investor Relations page of Novocure’s website, www.novocure.com/investors, and will be available for replay for at least 14 days following the call.
About Novocure
Novocure is a commercial-stage oncology company developing a proprietary therapy called Tumor Treating Fields, or TTFields, for the treatment of solid tumor cancers. Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania, and New York City. Additionally, the company has offices in Germany, Switzerland and Japan, and a research center in Haifa, Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.
Media and Investor Contact: Ashley Cordova 212-767-7558 [email protected]
